Pivanex 是丁酸的一种衍生物，是具有口服活性的HDAC抑制剂。Pivanex通过下调Bcr-Abl蛋白增强凋亡。Pivanex显示出抗转移和抗血管生成的活性。

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Pivanex has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Pivanex (200 μM) causes enhancement in the G2-M phase, moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle. Pivanex (100-500 μM) shows significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also increases apoptosis and caspase activity in K562 cells [1][2].

Pivanex treatment also marked delays in the end stage of disease as defined by the onset of body mass loss. Pivanex (200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice [3].

122110-53-6

C10H18O4

202.25

AN-9;Pivalyloxymethyl butyrate

DMSO:100 mg/mL (494.44 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years